Statin Therapy is Associated with Decreased Pulmonary Vascular Pressures in Severe COPD

REFERENCES

• Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107(5):1193–1198.
   PubMed Web of Science ®Google Scholar
• Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36(10):752–758.
   PubMed Web of Science ®Google Scholar
• Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159(1):158–164.
   PubMed Web of Science ®Google Scholar
• Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136(2):412–419.
   PubMed Web of Science ®Google Scholar
• Macnee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150(3):833–852.
   PubMed Web of Science ®Google Scholar
• Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5):892–905.
   PubMed Web of Science ®Google Scholar
• Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43(3):183–189.
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009; 4:337–349.
   PubMedGoogle Scholar
• Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128(4):2640–2646.
   PubMed Web of Science ®Google Scholar
• Melot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130(4):612–616.
   PubMed Web of Science ®Google Scholar
• Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31(4):759–764.
   PubMed Web of Science ®Google Scholar
• Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. Eur Respir J 1988; 1(8):716–720.
   PubMed Web of Science ®Google Scholar
• Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32(3):619–628.
   PubMed Web of Science ®Google Scholar
• Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109(1):7–15.
   Google Scholar
• Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285(3):H938–H945.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292(5):L1105–L1110.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172(8):987–993.
   PubMed Web of Science ®Google Scholar
• Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176(8):742–747.
   PubMed Web of Science ®Google Scholar
• Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008; 62(9):1373–1378.
   PubMed Web of Science ®Google Scholar
• Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009; 116(6):497–505.
   PubMed Web of Science ®Google Scholar
• Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30(4):458–470.
   PubMed Web of Science ®Google Scholar
• Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166(3):314–322.
   PubMed Web of Science ®Google Scholar
• Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127(5):1531–1536.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(2):189–194.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136(3):678–687.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008; 14(2):115–121.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179(1):35–40.
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(6):513–520.
   PubMed Web of Science ®Google Scholar
• Desai A, Fang JC. Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. Heart Fail Clin 2008; 4(1):87–97.
   PubMedGoogle Scholar
• Harris P, Segel N, Green I, Housley E. The influence of the airways resistance and alveolar pressure on the pulmonary vascular resistance in chronic bronhcitis. Cardiovasc Res 1968; 2(1):84–92.
   PubMed Web of Science ®Google Scholar
• Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002; 11(5):489–496.
   PubMed Web of Science ®Google Scholar
• Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6):1020–1025.
   PubMed Web of Science ®Google Scholar
• Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34(6):1281–1286.
   PubMed Web of Science ®Google Scholar
• Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002; 106(16):2118–2124.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004; 68(2):121–125.
   PubMed Web of Science ®Google Scholar
• Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104(3):317–324.
   PubMed Web of Science ®Google Scholar
• Smilde TJ, Van Den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000; 30(6):473–480.
   PubMed Web of Science ®Google Scholar
• Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106(23):2884–2887.
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23 Suppl 1):III39–III43.
   Web of Science ®Google Scholar
• Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18):2356–2363.
   PubMed Web of Science ®Google Scholar
• Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272(50):31725–31729.
   PubMed Web of Science ®Google Scholar
• O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105(2):213–217.
   PubMed Web of Science ®Google Scholar
• Alpert NR, LeWinter M, Mulieri LA, Hasenfuss G. Chemomechanical Energy Transduction in the Failing Heart. Heart Failure Reviews 1999; 4(3):281–295.
   Google Scholar
• Zheng X, Hu SJ. Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 2005; 26(6):696–704.
   PubMed Web of Science ®Google Scholar
• Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47(6):770–779.
   PubMed Web of Science ®Google Scholar
• Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest 2008; 134(4):808–814.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Washko GR, Yamashiro T, Estepar RS, Diaz A, Silverman EK, Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 2010; 181(3):218–225.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108(13):1640–1645.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291(4):L668–L676.
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003; 24(4):320–328.
   PubMed Web of Science ®Google Scholar
• Samdarshi TE, Taylor HA, Edwards DQ, Liebson PR, Sarpong DF, Shreenivas SS, Distribution and determinants of Doppler-derived diastolic flow indices in African Americans: the Jackson Heart Study (JHS). Am Heart J 2009; 158(2):209–216.
   PubMed Web of Science ®Google Scholar
• Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164(2):219–224.
   PubMed Web of Science ®Google Scholar
• Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130(6):993–998.
   PubMed Web of Science ®Google Scholar
• Bishop JM, Cross KW. Use of other physiological variables to predict pulmonary arterial pressure in patients with chronic respiratory disease. Multicentre study. Eur Heart J 1981; 2(6):509–517.
   PubMed Web of Science ®Google Scholar
• Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: A systematic review. Chest 2009; 136(3):734–743.
   PubMed Web of Science ®Google Scholar